Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Manylion Llyfryddiaeth
Prif Awduron:	Cree, BAC, Bennett, JL, Kim, HJ, Weinshenker, BG, Pittock, SJ, Wingerchuk, DM, Fujihara, K, Paul, F, Cutter, GR, Marignier, R, Green, AJ, Aktas, O, Hartung, H-P, Lublin, FD, Drappa, J, Barron, G, Madani, S, Ratchford, JN, She, D, Cimbora, D, Katz, E
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	Elsevier 2019

Eitemau Tebyg

Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism
gan: Ho Jin Kim, et al.
Cyhoeddwyd: (2023-12-01)

Treatment of Neuromyelitis Optica: Review and Recommendations.
gan: Kimbrough, D, et al.
Cyhoeddwyd: (2012)

Comparison of inebilizumab or rituximab in addition to glucocorticoid therapy for neuromyelitis optica spectrum disorders
gan: Chu-Yuan Lou, et al.
Cyhoeddwyd: (2024-06-01)

Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report
gan: Dominik Lehrieder, et al.
Cyhoeddwyd: (2023-11-01)

Treatment of neuromyelitis optica: Review and recommendations
gan: Kimbrough, D, et al.
Cyhoeddwyd: (2012)

Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trialResearch in context
gan: Jeffrey L. Bennett, et al.
Cyhoeddwyd: (2022-12-01)

A rare adverse effect in inebilizumab therapy for neuromyelitis optica spectrum disorder: a case report
gan: Xuefen Chen, et al.
Cyhoeddwyd: (2024-07-01)

Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
gan: Jyh Yung Hor, et al.
Cyhoeddwyd: (2020-06-01)

Case report: Transition from anti-CD20 therapy to inebilizumab for 14 cases of neuromyelitis optica spectrum disorder
gan: Benjamin Osborne, et al.
Cyhoeddwyd: (2024-04-01)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
gan: Pittock, S, et al.
Cyhoeddwyd: (2019)

Case report: Identification of Hepatitis B Virus in the cerebrospinal fluid of neuromyelitis optica spectrum disorders and successful treatment with ofatumumab and inebilizumab
gan: Linjun Cai, et al.
Cyhoeddwyd: (2024-02-01)

Atypical presentations of neuromyelitis optica
gan: Douglas Sato, et al.
Cyhoeddwyd: (2011-10-01)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
gan: Collongues, N, et al.
Cyhoeddwyd: (2013)

A case report of AQP4-IgG-seropositive refractory neuromyelitis optica spectrum disorder patient with Sjögren’s syndrome and pancytopenia treated with inebilizumab
gan: Shasha Li, et al.
Cyhoeddwyd: (2024-06-01)

B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
gan: Jeffrey L. Bennett, et al.
Cyhoeddwyd: (2024-10-01)

Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
gan: Fujihara, K, et al.
Cyhoeddwyd: (2014)

Treatment of neuromyelitis optica: an evidence based review
gan: Douglas Sato, et al.
Cyhoeddwyd: (2012-01-01)

Inebilizumab treatment in a patient with co-occurring AQP4-IgG positive neuromyelitis optica spectrum disorder and myasthenia gravis: a case report and literature review
gan: Xiaoqian Song, et al.
Cyhoeddwyd: (2025-01-01)

Neuromyelitis Optica
gan: Goyal V, et al.
Cyhoeddwyd: (2009-10-01)

Neuromyelitis optica
gan: Jacob Anu, et al.
Cyhoeddwyd: (2007-01-01)

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder
gan: Achim Berthele, et al.
Cyhoeddwyd: (2023-04-01)

Anti-aquaporin-4 antibodies in Devic’s neuromyelitis optica: therapeutic implications
gan: Romain Marignier, et al.
Cyhoeddwyd: (2010-09-01)

Differential diagnosis of neuromyelitis optica spectrum disorders
gan: Sung-Min Kim, et al.
Cyhoeddwyd: (2017-07-01)

Racial differences in neuromyelitis optica spectrum disorder
gan: Kim, S, et al.
Cyhoeddwyd: (2018)

Case Report: In Situ Expression of a Proliferation-Inducing Ligand in Neuromyelitis Optica
gan: Laurie Baert, et al.
Cyhoeddwyd: (2021-08-01)

The borderland of neuromyelitis optica.
gan: Matthews, L, et al.
Cyhoeddwyd: (2009)

Pregnancy and neuromyelitis optica
gan: Qiu-ying MA, et al.
Cyhoeddwyd: (2016-10-01)

Influence of pregnancy on neuromyelitis optica spectrum disorder.
gan: Kim, W, et al.
Cyhoeddwyd: (2012)

The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab
gan: Philippe Nicolas, et al.
Cyhoeddwyd: (2019-11-01)

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.
gan: Mealy, M, et al.
Cyhoeddwyd: (2014)

Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder
gan: Stacey L. Clardy, et al.
Cyhoeddwyd: (2024-05-01)

Seronegative Neuromyelitis Optica Spectrum - The challenges on disease definition and pathogenesis
gan: Douglas Kazutoshi Sato, et al.
Cyhoeddwyd: (2014-06-01)

Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
gan: Paul, F, et al.
Cyhoeddwyd: (2007)

Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
gan: Friedemann Paul, et al.
Cyhoeddwyd: (2007-04-01)

Use of mitoxantrone in neuromyelitis optica.
gan: Kitley, J, et al.
Cyhoeddwyd: (2011)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
gan: Elsone, L, et al.
Cyhoeddwyd: (2012)

Prognosis of Relapsing Neuromyelitis Optica
gan: J Gordon Millichap
Cyhoeddwyd: (2003-03-01)

Neuromyelitis optica spectrum disorder
gan: Simon Broadley, et al.
Cyhoeddwyd: (2017-09-01)

Neuromyelitis Optica: Case Report
gan: Deniz Tuncel, et al.
Cyhoeddwyd: (2008-06-01)

Autoantibodies in patients with neuromyelitis optica
gan: Xin FAN, et al.
Cyhoeddwyd: (2016-10-01)